EP1150701A4 - Zielansteuernde pro-apoptotische konjugate und methoden zu deren verwendung - Google Patents

Zielansteuernde pro-apoptotische konjugate und methoden zu deren verwendung

Info

Publication number
EP1150701A4
EP1150701A4 EP00911617A EP00911617A EP1150701A4 EP 1150701 A4 EP1150701 A4 EP 1150701A4 EP 00911617 A EP00911617 A EP 00911617A EP 00911617 A EP00911617 A EP 00911617A EP 1150701 A4 EP1150701 A4 EP 1150701A4
Authority
EP
European Patent Office
Prior art keywords
methods
same
homing pro
apoptotic conjugates
apoptotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00911617A
Other languages
English (en)
French (fr)
Other versions
EP1150701A2 (de
Inventor
H Michael Ellerby
Dale E Bredesen
Renata Pasqualini
Erkki I Ruoslahti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Publication of EP1150701A2 publication Critical patent/EP1150701A2/de
Publication of EP1150701A4 publication Critical patent/EP1150701A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00911617A 1999-01-22 2000-01-21 Zielansteuernde pro-apoptotische konjugate und methoden zu deren verwendung Ceased EP1150701A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23590299A 1999-01-22 1999-01-22
US235902 1999-01-22
PCT/US2000/001602 WO2000042973A2 (en) 1999-01-22 2000-01-21 Homing pro-apoptotic conjugates and methods of using same

Publications (2)

Publication Number Publication Date
EP1150701A2 EP1150701A2 (de) 2001-11-07
EP1150701A4 true EP1150701A4 (de) 2003-03-26

Family

ID=22887331

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00911617A Ceased EP1150701A4 (de) 1999-01-22 2000-01-21 Zielansteuernde pro-apoptotische konjugate und methoden zu deren verwendung

Country Status (5)

Country Link
EP (1) EP1150701A4 (de)
JP (1) JP4531267B2 (de)
AU (1) AU770381B2 (de)
CA (1) CA2359633A1 (de)
WO (1) WO2000042973A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520808A (ja) * 2000-01-21 2003-07-08 ザ バーナム インスティチュート プロアポトーシス活性を有するキメラ前立腺ホーミングペプチド
JP2003522183A (ja) * 2000-02-02 2003-07-22 トランジェーヌ、ソシエテ、アノニム ターゲッティングペプチド
CA2421872A1 (en) 2000-09-11 2002-03-14 Institut Pasteur Mechanism of mitochondrial membrane permeabilization by hiv-1 vpr, mimetics of vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of vpr with ant
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
ATE419861T1 (de) * 2001-11-08 2009-01-15 Burnham Inst Peptide mit homing für lymphgefässtumor und ihre verwendung
EP1346729A1 (de) * 2002-03-19 2003-09-24 Cardiovascular Research Institute Maastricht Zielgerichtete Therapie der myokardialen Angiogenese durch CD13/APN
WO2004007557A2 (en) * 2002-07-12 2004-01-22 Novo Nordisk A/S Tf antagonist
CA2519826A1 (en) 2003-03-24 2004-10-07 Nippon Medical School Foundation Cell death-inducing fusion gene specifically acting on cancer and product thereof
GB0312309D0 (en) * 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
US7598341B2 (en) 2003-10-31 2009-10-06 Burnham Institue For Medical Research Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
CA2594927A1 (en) * 2004-03-31 2005-10-13 Buck Institute Hunter-killer peptides and methods of use
CN102558334B (zh) * 2004-09-07 2016-08-03 伯纳姆研究院 选择性锚定到心脏脉管系统上的肽和相关结合物和方法
AU2006320327A1 (en) * 2005-12-01 2007-06-07 Duke University Compounds and methods for inhibiting apoptosis
FI121959B (fi) * 2008-05-09 2011-06-30 Pirjo Laakkonen Aivokasvaimiin hakeutuva peptidi
EP2414389A1 (de) * 2009-04-01 2012-02-08 Schmidt-Wolf, Ingo Auf tumore zielende peptide und therapeutische und diagnostische zusammensetzungen, die die peptide enthalten
JP2013525285A (ja) * 2010-04-08 2013-06-20 サンフォード−バーナム メディカル リサーチ インスティテュート 化合物の送達を増強するための方法および組成物
WO2016172515A1 (en) 2015-04-23 2016-10-27 Sanford Burnham Prebys Medical Discovery Institute Targeted delivery system and methods of use therefor
KR101741594B1 (ko) * 2015-06-30 2017-05-30 경북대학교 산학협력단 암세포 및 종양관련 대식세포를 동시에 표적하는 융합 펩타이드를 유효성분으로 포함하는 항암 및 암 전이 억제용 약학적 조성물
WO2017124147A1 (en) * 2016-01-19 2017-07-27 The University Of Western Australia Novel biomolecule conjugates and uses therefor
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11021529B2 (en) 2017-03-03 2021-06-01 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
CN108314741B (zh) * 2018-03-22 2021-08-03 中国人民解放军第四军医大学 一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法
EP4139327A4 (de) * 2020-04-22 2024-10-02 Oncovolution, LLC Peptid-platin-komplexe und verfahren zur verwendung davon
CN112830975B (zh) * 2021-02-02 2023-03-10 西南交通大学 α-螺旋构象稳定的促凋亡双环多肽及制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789542A (en) * 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
US5773292A (en) * 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
EP0938505B1 (de) * 1996-05-31 2002-03-06 Health Research, Inc. Monoklonale Antikörper gegen Endoglin und ihre Verwendung in der anti-Angiogenese-Therapie
WO1998010795A2 (en) * 1996-09-10 1998-03-19 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
ATE407943T1 (de) * 1998-03-13 2008-09-15 Burnham Inst Zielsuchende verbindungen für verschiedene organe und gewebe

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAVADPOUR MARYAM M ET AL: "De novo antimicrobial peptides with low mammalian cell toxicity.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 16, 1996, pages 3107 - 3113, XP002228388, ISSN: 0022-2623 *
See also references of WO0042973A3 *

Also Published As

Publication number Publication date
JP4531267B2 (ja) 2010-08-25
CA2359633A1 (en) 2000-07-27
WO2000042973A3 (en) 2000-09-28
WO2000042973A2 (en) 2000-07-27
EP1150701A2 (de) 2001-11-07
JP2002535258A (ja) 2002-10-22
AU770381B2 (en) 2004-02-19
AU3348600A (en) 2000-08-07

Similar Documents

Publication Publication Date Title
IL183948A0 (en) Conjugates of peg-urate oxidase and use thereof
HRP20060251B1 (hr) Supstituirani oksazolidinoni i njihova uporaba
AP2002002505A0 (en) Novel compostition and use
IL148247A (en) Vaccine and its uses
AU8967998A (en) Antibiotic-ligand conjugates and methods of use thereof
GB9924351D0 (en) Immunomodulation methods and compositions
IL146842A0 (en) Polymer conjugates of hedgehog proteins and uses
HUP0301076A3 (en) Linezolid-crystal form ii and preparation thereof
AUPQ342599A0 (en) Conjugates and uses thereof
EP1147213A4 (de) RGS-ENTHALTENDE MOLEKüLE UND DEREN VERWENDUNGEN
GB0023323D0 (en) Arylhydantoin derivatives and uses thereof
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
EG22491A (en) Rest-breaking composition and use thereof
IL131719A0 (en) Iren protein its preparation and use
AU2136401A (en) P450rai-2 and related proteins
GB9922135D0 (en) Compositions and uses
GB0318107D0 (en) ›-Secretase enzyme compositions and methods
AU6084598A (en) Antibiotic-ligand conjugates and methods of use thereof
AU6204400A (en) Novel kinases and uses thereof
GB9929581D0 (en) Comjpositions and their use
NZ513920A (en) Novel proteins and uses thereof
AU3347300A (en) Desmethylsildenafil compositions and methods
GB9902051D0 (en) Compositions and methods
GB9928549D0 (en) Compositions and methods
GB9916506D0 (en) Compositions and methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010806

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PASQUALINI, RENATA

Inventor name: RUOSLAHTI, ERKKI, I.

Inventor name: ELLERBY, H., MICHAEL

Inventor name: BREDESEN, DALE, E.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RUOSLAHTI, ERKKI, I.

Inventor name: PASQUALINI, RENATA

Inventor name: ELLERBY, H., MICHAEL

Inventor name: BREDESEN, DALE, E.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BREDESEN, DALE, E.

Inventor name: ELLERBY, H., MICHAEL

Inventor name: PASQUALINI, RENATA

Inventor name: RUOSLAHTI, ERKKI, I.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 39/00 B

Ipc: 7A 61K 38/00 A

Ipc: 7C 07K 5/00 B

Ipc: 7C 07K 4/00 B

Ipc: 7C 07K 2/00 B

Ipc: 7C 07K 17/00 B

Ipc: 7C 07K 14/00 B

Ipc: 7A 61K 47/48 B

Ipc: 7A 61K 39/02 B

Ipc: 7A 61K 38/04 B

Ipc: 7C 07K 16/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030206

17Q First examination report despatched

Effective date: 20040617

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20060820

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BREDESEN, DALE, E.

Inventor name: PASQUALINI, RENATA

Inventor name: RUOSLAHTI, ERKKI, I.

Inventor name: ELLERBY, H., MICHAEL